These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36901951)

  • 21. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
    Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
    Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
    Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
    Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
    Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
    Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ
    J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
    Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
    Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
    Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
    Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
    Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
    Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
    Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
    J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
    Johnson AS; Crandall H; Dahlman K; Kelley MC
    J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceritinib Enhances the Efficacy of Trametinib in
    Verduzco D; Kuenzi BM; Kinose F; Sondak VK; Eroglu Z; Rix U; Smalley KSM
    Mol Cancer Ther; 2018 Jan; 17(1):73-83. PubMed ID: 29133622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
    Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trametinib in the treatment of melanoma.
    Thota R; Johnson DB; Sosman JA
    Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.